Stem Cell Treatment for Glaucoma

Stem Cell Treatments for Glaucoma are currently available at SIRM


Stem cell treatment for glaucoma

Glaucoma is an eye disorder in which the optic nerve suffers damage, permanently damaging vision in the affected eye(s) and progressing to complete blindness if untreated. It is often, but not always, associated with increased pressure of the fluid in the eye (aqueous humour). The term 'ocular hypertension' is used for cases having constantly raised intraocular pressure (IOP) without any associated optic nerve damage. Conversely, the term 'normal' or 'low tension glaucoma' is suggested for the typical visual field defects when associated with a normal or low IOP.

The nerve damage involves loss of retinal ganglion cells in a characteristic pattern. There are many different subtypes of glaucoma, but they can all be considered a type of optic neuropathy. Raised intraocular pressure is a significant risk factor for developing glaucoma. One person may develop nerve damage at a relatively low pressure, while another person may have high eye pressure for years and yet never develop damage. Untreated glaucoma leads to permanent damage of the optic nerve and resultant visual field loss, which can progress to blindness.

Glaucoma can be divided roughly into two main categories

  • open angle: Open angle, chronic glaucoma tends to progress at a slower rate and patients may not notice they have lost vision until the disease has progressed significantly.
  • closed angle: Closed angle glaucoma can appear suddenly and is often painful; visual loss can progress quickly, but the discomfort often leads patients to seek medical attention before permanent damage occurs.


Stem Cell Treatment for Glaucoma and stem cell therapy.

Stem Cell treatment studies and stem cell protocols from the NIH database:

Related Articles [Penetrating Limbokeratoplasty for Gelatinous Corneal Dystrophy]. Klin Monbl Augenheilkd. 2017 Jul 06;: Authors: Lang SJ, Böhringer D, Reinhard T Abstract Background Gelatinous corneal dystrophy is a very rare disease in Europe and North America. Patients suffer from pain, photophobia and loss of vision, usually before the age of 20. Transplantation of limbal stem cells was proposed due to the high rate of recurrence after conventional penetrating keratoplasty. We present the results of penetrating limbokeratoplasty, a combined transplantation of cornea and limbal stem cells, in patients with gelatinous corneal dystrophy. Methods We present a series of 7 consecutive eyes with gelatinous corneal dystrophy, which were treated with penetrating limbokeratoplasty-4 eyes of 3 patients had already undergone multiple conventional corneal transplantations. We evaluated the follow-up regarding recurrences of the disease, graft rejections, clear graft survival and incidence of secondary glaucoma with the Kaplan-Meier method. Results Median age at surgery was 35 years. Postoperative treatment included topical steroids and systemic mycophenolate mofetil in all patients. Median graft survival was 6 years. Median time to a recurrence was 3 years. Median time to the first endothelial graft rejection was 2.5 years. Conclusion Penetrating limbokeratoplasty offers a possibility to restore visual acuity over a long period of time. However, gelatinous corneal dystrophy remains a therapeutic challenge. Even with simultaneous transplantation of cornea and limbal stem cells, recurrences of the disease cannot be prevented permanently. This is also connected with discontinuing a sufficient local and systemic immunosuppression. PMID: 28683480 [PubMed - as supplied by publisher]

Quick Contact Form